about
Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope proteinAssociation of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese populationA retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.Retortamonas intestinalis in the pancreatic juice of a patient with small nodular lesions of the main pancreatic duct.Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis.Lack of association between the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population.Advanced hepatocellular carcinoma responds to MK615, a compound extract from the Japanese apricot "Prunus mume".Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.Enhanced pregenomic RNA levels and lowered precore mRNA transcription efficiency in a genotype A hepatitis B virus genome with C1766T and T1768A mutations obtained from a fulminant hepatitis patient.Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.Zinc is a negative regulator of hepatitis C virus RNA replication.Association of a single nucleotide polymorphism upstream of ICOS with Japanese autoimmune hepatitis type 1.Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells.Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element.Fatal fulminant hepatitis caused by infection with subgenotype A1 hepatitis B virus with C1766T/T1768A core promoter mutations.Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells.Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype.Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial.Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases.Association of a single nucleotide polymorphism in TNIP1 with type-1 autoimmune hepatitis in the Japanese populationPotent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infectionGastric Yolk Sac Tumor Complicated with Beta-Human Chorionic Gonadotropin-Producing MetastasesPreventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infectionSystemic Sclerosis after Interferon Alphacon-1 Therapy for Hepatitis CPOGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitisAdenosquamous Carcinoma of the Choledochusβ-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular CarcinomaIntratumoral Hemorrhage of Liver Metastasis from a Rectal Neuroendocrine TumorAnalyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective studyIntegrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionRole of deleterious single nucleotide variants in the coding regions of TNFAIP3 for Japanese autoimmune hepatitis with cirrhosisImpact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study
P50
Q24338469-1D0C639E-BE36-4966-89C3-AF93F1472518Q28535584-2B522283-E8C5-424B-96BB-7FDA2988E823Q33395398-0949C229-F413-48AE-86D4-2B5D13B3604AQ33433261-A60D75E6-397F-43E6-A4FC-718CE9D2C8A3Q33940139-35C400A4-7ED6-4DE8-A14D-47C27DC659AEQ35843599-8FE567FB-0A07-4E6E-8298-EDFF0523D94BQ35864855-A168A0BA-E596-400D-8C97-5B19788929B6Q37266343-4F6E1526-84FC-4946-8017-8EB910756560Q39034887-4331D5D7-1C2A-4A14-AB55-8CA69AF866A3Q39544198-9ECBB6ED-4E07-4FBD-8174-85A39E985036Q40060636-57743582-AE54-497B-8262-26A2290A7D61Q40221698-27B6C255-C974-4334-94BC-4DFA9EA3EE26Q40424805-E955EB32-6418-4271-82CF-9487B27DFF7AQ40583906-921E5D57-BCE8-47DA-8A56-7FDD83CA7F07Q40588114-1D6B45A8-5DEA-46AB-B56F-9C7B5A2E6B28Q40627485-D08DC5A2-1E2F-40EB-9B61-5CF776E19539Q40680143-70A9750C-D893-4756-9406-791DD38C41DBQ40902950-DCCFD2CA-332B-4270-B762-6B2CAAB8A1A5Q41930211-4EBF5A76-A0BD-4F10-BC2A-542AC878A134Q47133202-33C28CFE-1A4C-4765-85C7-19083F39DCD5Q48127743-9E4614AF-4490-45B0-A67A-EFD29E711163Q48189352-D5DC1FAF-949C-42E6-BD75-91CD9EDD52BFQ50513946-A258F795-749A-4AAD-9B7A-A4844B61937CQ53165084-BDD31765-A085-4FE5-B4E3-50A11F293926Q58171177-F3BACE93-F143-43C8-A728-EB0CD78FFF6FQ58171204-AD0C72D3-5967-4EC8-BB33-BE29E41FE152Q58171339-A7331A09-02BB-4B9A-B86E-CE66BD4B72FAQ58171365-85CBA924-191C-4598-9A6E-E353A7FBE6D1Q58171374-C23BE2BF-4EA6-47D8-A104-F1A28D356A63Q60909951-51A46622-1253-468D-A84C-17830B5BB1E9Q60955494-07DF4D15-458B-48CC-ACBE-46B490ADDECFQ61451151-9A524851-4A7D-44E0-AA2B-87AF169422CDQ64231987-1700FCB9-832D-4B4C-9130-F35A48A59A87Q91415660-75909F47-4A68-489D-9A30-F72B5FD450B4Q91417861-54E46E7E-4576-4586-9A3C-6EA8507A7DD6Q92345448-3668E6B9-C265-46C3-A51F-198D885545B7Q92356629-A8D73E5E-3739-45C4-85FA-14CDBBAAAEB9Q92658310-E8EBB531-8EE2-4849-9758-D536328606BB
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Atsushi Naganuma
@ast
Atsushi Naganuma
@en
Atsushi Naganuma
@es
Atsushi Naganuma
@nl
type
label
Atsushi Naganuma
@ast
Atsushi Naganuma
@en
Atsushi Naganuma
@es
Atsushi Naganuma
@nl
prefLabel
Atsushi Naganuma
@ast
Atsushi Naganuma
@en
Atsushi Naganuma
@es
Atsushi Naganuma
@nl
P106
P1153
7004364046
P31
P496
0000-0003-0663-0102